Paget’s disease of bone
▶BY MOUTH
▶Adult: 30 mg daily for 2 months, course may be
repeated if necessary after at least 2 months
Treatment of postmenopausal osteoporosis to reduce risk
of vertebral or hip fractures
▶BY MOUTH
▶Adult (female): 5 mg daily, alternatively 35 mg once
weekly.
Prevention of osteoporosis (including corticosteroid-
induced osteoporosis) in postmenopausal women
▶BY MOUTH
▶Adult (female): 5 mg daily.
Treatment of osteoporosis in men at high risk of fractures
▶BY MOUTH
▶Adult (male): 35 mg once weekly.
PDF page 791
NICE decisions
▶Bisphosphonates for treating osteoporosis (updated July
2019) NICE TA464
This technology appraisal guidance should be applied
clinically in conjunction with:
. NICE guideline on osteoporosis (CG146), which defines
who is eligible for osteoporotic fracture risk assessment.
. NICE quality standard on osteoporosis (QS149), which
defines the clinical intervention thresholds for the
10-year fracture probability of a major osteoporotic
fracture, in those patients who have undergone fracture
risk assessment.
Risedronate sodium is recommended as an option for
treating osteoporosis in patients:
. who are eligible for risk assessment as defined in the full
NICE guideline and quality standard on osteoporosis,
and
. who have been assessed as being at higher risk of
osteoporotic fragility fracture using the methods
recommended in the full NICE guideline and quality
standard on osteoporosis, and
. when bisphosphonate treatment is appropriate, taking
into account their risk of fracture, their risk of adverse
effects from bisphosphonates, and their clinical
circumstances and preferences.
Patients whose treatment was started within the NHS
before this guidance was published should have the option
to continue treatment, without change to their funding
arrangements, until they and their NHS clinician consider
it appropriate to stop.
www.nice.org.uk/guidance/ta464
PDF page 792
